Download PDF
Pharmacopsychiatry 1992; 25(6): 261-264
DOI: 10.1055/s-2007-1014418
© Georg Thieme Verlag KG Stuttgart · New York

Brofaromine in Panic Disorder: A Pilot Study with a New Reversible Inhibitor of Monoamine Oxidase-A

Brofaromin in der Behandlung von Panik-Störung: Eine Pilot-Studie mit einem neuen reversiblen Hemmer der Monoamin Oxidase-AD.  Garcia-Borreguero , C. J. Lauer , A.  Özdaglar1 , K.  Wiedemann , F.  Holsboer , J. -C. Krieg
  • Max Planck Institute of Psychiatry, Clinical Institute, Department of Psychiatry, Munich, Germany
  • 1Department of Psychiatry, University of Freiburg, Freiburg, Germany
Further Information

Publication History

Publication Date:
13 March 2008 (online)

Also available at
 PDF Download  Permissions and Reprints
Preview

Abstract

The therapeutic efficacy of brofaromine - a new reversible and short acting MAO-A inhibitor - was evaluated in 14 inpatients with a panic disorder In an open trial, the patients were treated with placebo during the first week and with 150mg brofaromine per day during the following four weeks. In all patients a distinct improvement in both anxiety and depressive symptoms was observed under the active drug. Treatment outcome was the same in patients with and without a concomitant major depressive episode. No side effects of any note were reported. Our findings suggest that the MAO-A inhibitor brofaromine is an effective drug in the treatment of anxiety disorders.